Nicox (ALCOX.PA) Shares Decline Amid Volatile Trading
On Thursday 22 October 2026, Nicox S.A. (ticker ALCOX.PA) experienced a decline of ‑2.31 % within a 24‑hour trading window that concluded at 08:41 AM Central Europe. The share price settled at EUR 0.30 on the principal exchanges, reflecting a modest yet noteworthy drop from the prior close.
Trading Metrics
- Shares Outstanding: 89.3 million
- Market Capitalisation: EUR 26.2 million
- Volume in Last 24 Hours: EUR 29.6 k worth of shares exchanged
- Year‑to‑Date Performance: The stock has slipped ‑13.7 % since the end of last month.
- 200‑Day Simple Moving Average: EUR 0.38
- 52‑Week Range: Highest price of EUR 0.57 (25 February 2026); lowest price of EUR 0.28 (20 October 2026).
Comparative Performance of Related Shares
| Stock | Ticker | 24‑Hour Move | Current Price | Market Cap | Notable Ratios |
|---|---|---|---|---|---|
| Artea | ARTE.PA | 0 % | EUR 5.5 | EUR 26.3 million | – |
| Canal+ | CAN.L | ‑0.49 % | GBX 242 | GBX 3.2 billion | – |
| Hipay | ALHYP.PA | +1.42 % | EUR 4.3 | EUR 27 million | P/E 6.58 |
| Odyssee | ALODY.PA | +1.22 % | EUR 16.6 | EUR 26.5 million | – |
| Smaio | ALSMA.PA | +1.82 % | EUR 5.6 | EUR 31 million | – |
Nicox’s movement appears to be part of a broader pattern of modest gains among its peers, with the exception of Canal+, which trended slightly lower.
Company Overview
Nicox S.A. is a French‑based biotechnology firm headquartered in Valbonne, specialising in therapeutic solutions for ophthalmic diseases. Established in 1996, the company’s portfolio includes:
- Vyzulta™ – a treatment that lowers intraocular pressure.
- NCX 470 – a nitric‑oxide donating candidate targeting glaucoma.
- Stand‑alone NO donors for specific ocular conditions.
- ZERVIATE – a cetirizine eye drop for allergic conjunctivitis.
- NCX 4280 – an ophthalmic solution for morning ocular congestion.
- NCX 4251 – a fluticasone propionate formulation for blepharitis.
Nicox maintains collaborations with industry leaders such as Bausch + Lomb, AstraZeneca, Merck, Pfizer, Ironwood Pharmaceuticals, and Novaliq GmbH. The company is dual‑listed on the NYSE and Euronext Paris exchanges and maintains an active research and development pipeline aimed at expanding its therapeutic reach.
For further information, the company’s official website is available at www.nicox.com .
